**FDA Limits Use of Johnson & Johnson Covid-19 Shot Due to Serious Blood Clot Risks**
In a shocking development, the US FDA has announced limitations on the use of the Johnson & Johnson (J&J)/Janssen Covid-19 shot due to the serious risk of blood clots. This unexpected move raises concerns for citizens who have already received the controversial vaccine.
The FDA has now restricted the use of the J&J Covid-19 shot to individuals aged 18 and older, and only for cases where other authorized Covid-19 vaccines are not accessible or clinically suitable. This bold decision comes after an investigation highlighted the risk of thrombosis with thrombocytopenia syndrome (TTS) – a rare and potentially life-threatening condition involving blood clots and low blood platelet levels – following the administration of the Janssen vaccine.
The FDA has also reported individuals experiencing anaphylactic reactions after receiving an mRNA Covid-19 shot. Moreover, on May 18, 2023, the CDC announced that Johnson & Johnson/Janssen Covid-19 shots are no longer available in the US, and all remaining doses are to be disposed of according to the law.
In a surprising move, Janssen Biotech, a pharmaceutical subsidiary of Johnson & Johnson, voluntarily requested the withdrawal of the Emergency Use Authorization (EUA) for their Covid-19 vaccine. This decision was prompted by factors such as the expiration of the final vaccine lots purchased by the US government, a lack of demand for new lots within the US, and no plans to update the vaccine strain composition to address emerging virus variants.
In response to Janssen’s request, the FDA revoked the EUA for the Janssen Covid-19 vaccine on June 1, 2023. This unexpected revocation of the EUA was seemingly unlikely until Johnson & Johnson itself approached the FDA with the request.
**Johnson & Johnson Covid-19 Shot Faces Stark Limitations as FDA Revokes Emergency Use Authorization**